Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Systemic Immunosuppressant — Bullous Diseases / Autoimmune Dermatoses

Mycophenolate Mofetil

Brand names: CellCept, Myfenax

Mycophenolate mofetil is an immunosuppressant used after transplantation and as a steroid-sparing agent in various autoimmune and inflammatory conditions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits inosine monophosphate dehydrogenase, selectively suppressing T- and B-lymphocyte proliferation.

Prescribing in practice

  • It is highly teratogenic and causes miscarriage — strict pregnancy prevention is required for anyone able to become pregnant, with relevant advice for men too (MHRA).
  • Bone-marrow suppression and increased infection risk (including reactivation and, rarely, PML) occur; gastrointestinal effects are common.
  • Avoid live vaccines; absorption is reduced by some antacids and by sevelamer.

Monitoring

Monitor full blood count regularly (especially early), review for infection, and confirm pregnancy-prevention measures.

Counselling the patient

  • Use effective contraception and avoid pregnancy — it can seriously harm a baby.
  • Report sore throat, fever, bruising or other signs of infection.
  • Take it consistently and attend monitoring blood tests.

Evidence & guidelines

Used after transplantation and as a steroid-sparing immunosuppressant, with strict pregnancy-prevention requirements (MHRA).

Reference: EMA Pregnancy Prevention Programme; BAD Pemphigus Guidelines; BAD Bullous Pemphigoid Guidelines 2012 (updated); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways